First Targeted Therapy for Glioma Headed for FDA Approval
A first-in-class targeted therapy for low-grade glioma could gain FDA approval as early as spring 2024. Here are three things you should know about the emerging drug “vorasidenib.”
Sign up for our bi-monthly email to get the latest news on treatments, support, and stories from the brain tumor community.
